Product
Antigen-specific DTH
1 clinical trial
1 indication
Indication
Lung CancerClinical trial
Phase I Study of MIDRIXNEO-LUNG, an Autologous Neoantigen-targeted Dendritic Cell Immunotherapy in Patients With Non-small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-02-01